Your browser doesn't support javascript.
Adeno-associated virus type 2 in US children with acute severe hepatitis.
Servellita, Venice; Sotomayor Gonzalez, Alicia; Lamson, Daryl M; Foresythe, Abiodun; Huh, Hee Jae; Bazinet, Adam L; Bergman, Nicholas H; Bull, Robert L; Garcia, Karla Y; Goodrich, Jennifer S; Lovett, Sean P; Parker, Kisha; Radune, Diana; Hatada, April; Pan, Chao-Yang; Rizzo, Kyle; Bertumen, J Bradford; Morales, Christina; Oluniyi, Paul E; Nguyen, Jenny; Tan, Jessica; Stryke, Doug; Jaber, Rayah; Leslie, Matthew T; Lyons, Zin; Hedman, Hayden D; Parashar, Umesh; Sullivan, Maureen; Wroblewski, Kelly; Oberste, M Steven; Tate, Jacqueline E; Baker, Julia M; Sugerman, David; Potts, Caelin; Lu, Xiaoyan; Chhabra, Preeti; Ingram, L Amanda; Shiau, Henry; Britt, William; Gutierrez Sanchez, Luz Helena; Ciric, Caroline; Rostad, Christina A; Vinjé, Jan; Kirking, Hannah L; Wadford, Debra A; Raborn, R Taylor; St George, Kirsten; Chiu, Charles Y.
  • Servellita V; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Sotomayor Gonzalez A; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Lamson DM; Wadsworth Center, New York State Department of Health, David Axelrod Institute, Albany, NY, USA.
  • Foresythe A; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Huh HJ; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Bazinet AL; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Bergman NH; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA.
  • Bull RL; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA.
  • Garcia KY; Federal Bureau of Investigation Laboratory Division/Scientific Response and Analysis Unit, Quantico, VA, USA.
  • Goodrich JS; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA.
  • Lovett SP; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA.
  • Parker K; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA.
  • Radune D; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA.
  • Hatada A; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA.
  • Pan CY; California Department of Public Health, Richmond, CA, USA.
  • Rizzo K; California Department of Public Health, Richmond, CA, USA.
  • Bertumen JB; California Department of Public Health, Richmond, CA, USA.
  • Morales C; California Department of Public Health, Richmond, CA, USA.
  • Oluniyi PE; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Nguyen J; California Department of Public Health, Richmond, CA, USA.
  • Tan J; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Stryke D; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Jaber R; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Leslie MT; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Lyons Z; Florida Department of Health, Tallahassee, FL, USA.
  • Hedman HD; Illinois Department of Public Health, Chicago, IL, USA.
  • Parashar U; North Carolina Department of Health and Human Services, Raleigh, NC, USA.
  • Sullivan M; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Wroblewski K; South Dakota Department of Health, Pierre, SD, USA.
  • Oberste MS; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Tate JE; Association for Public Health Laboratories, Silver Spring, MD, USA.
  • Baker JM; Association for Public Health Laboratories, Silver Spring, MD, USA.
  • Sugerman D; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Potts C; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Lu X; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Chhabra P; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Ingram LA; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Shiau H; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Gutierrez Sanchez LH; Alabama Department of Public Health, Montgomery, AL, USA.
  • Ciric C; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Rostad CA; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Vinjé J; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Kirking HL; Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Wadford DA; Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Raborn RT; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • St George K; Centers for Disease Control and Prevention, Atlanta, CA, USA.
  • Chiu CY; California Department of Public Health, Richmond, CA, USA.
Nature ; 617(7961): 574-580, 2023 May.
Article in English | MEDLINE | ID: covidwho-2326179
ABSTRACT
As of August 2022, clusters of acute severe hepatitis of unknown aetiology in children have been reported from 35 countries, including the USA1,2. Previous studies have found human adenoviruses (HAdVs) in the blood from patients in Europe and the USA3-7, although it is unclear whether this virus is causative. Here we used PCR testing, viral enrichment-based sequencing and agnostic metagenomic sequencing to analyse samples from 16 HAdV-positive cases from 1 October 2021 to 22 May 2022, in parallel with 113 controls. In blood from 14 cases, adeno-associated virus type 2 (AAV2) sequences were detected in 93% (13 of 14), compared to 4 (3.5%) of 113 controls (P < 0.001) and to 0 of 30 patients with hepatitis of defined aetiology (P < 0.001). In controls, HAdV type 41 was detected in blood from 9 (39.1%) of the 23 patients with acute gastroenteritis (without hepatitis), including 8 of 9 patients with positive stool HAdV testing, but co-infection with AAV2 was observed in only 3 (13.0%) of these 23 patients versus 93% of cases (P < 0.001). Co-infections by Epstein-Barr virus, human herpesvirus 6 and/or enterovirus A71 were also detected in 12 (85.7%) of 14 cases, with higher herpesvirus detection in cases versus controls (P < 0.001). Our findings suggest that the severity of the disease is related to co-infections involving AAV2 and one or more helper viruses.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adenovirus Infections, Human / Dependovirus / Coinfection / Hepatitis Type of study: Etiology study / Observational study / Prognostic study Limits: Child / Humans Language: English Journal: Nature Year: 2023 Document Type: Article Affiliation country: S41586-023-05949-1

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adenovirus Infections, Human / Dependovirus / Coinfection / Hepatitis Type of study: Etiology study / Observational study / Prognostic study Limits: Child / Humans Language: English Journal: Nature Year: 2023 Document Type: Article Affiliation country: S41586-023-05949-1